NASDAQ:ZYNE Zynerba Pharmaceuticals (ZYNE) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$1.26▼$1.3450-Day Range$1.21▼$1.3952-Week Range$0.25▼$1.40Volume862,700 shsAverage Volume515,333 shsMarket Capitalization$70.12 millionP/E RatioN/ADividend YieldN/APrice Target$1.11 Stock AnalysisStock Analysis Get Zynerba Pharmaceuticals alerts: Email Address Zynerba Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside14.6% Downside$1.11 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.84) to ($0.49) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.02 out of 5 starsMedical Sector934th out of 936 stocksPharmaceutical Preparations Industry436th out of 436 stocks 1.0 Analyst's Opinion Consensus RatingZynerba Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageZynerba Pharmaceuticals has received no research coverage in the past 90 days.Read more about Zynerba Pharmaceuticals' stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for ZYNE. Previous Next 0.0 Dividend Strength Dividend YieldZynerba Pharmaceuticals does not currently pay a dividend.Dividend GrowthZynerba Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ZYNE. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 1 people have searched for ZYNE on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Zynerba Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders13.04% of the stock of Zynerba Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 11.23% of the stock of Zynerba Pharmaceuticals is held by institutions.Read more about Zynerba Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Zynerba Pharmaceuticals are expected to grow in the coming year, from ($0.84) to ($0.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zynerba Pharmaceuticals is -1.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Zynerba Pharmaceuticals is -1.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioZynerba Pharmaceuticals has a P/B Ratio of 1.29. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Zynerba Pharmaceuticals Stock (NASDAQ:ZYNE)Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.Read More Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. ZYNE Stock News HeadlinesOctober 31, 2023 | finance.yahoo.comHarmony Biosciences Reports Strong Third Quarter 2023 Financial ResultsOctober 13, 2023 | fool.comWhy Shares of Harmony Bioscience Are Falling on FridayJuly 27, 2024 | Paradigm Press (Ad)Musk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840.October 11, 2023 | markets.businessinsider.comNew Possibilities For Cannabinoid Treatments: Acquisition To Transform Neuropsychiatric Disorder TherapiesOctober 11, 2023 | finance.yahoo.comHARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINEOctober 4, 2023 | finance.yahoo.comImportant Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and InstructionsSeptember 29, 2023 | finance.yahoo.com20 Countries With Highest Rate of EpilepsySeptember 29, 2023 | finance.yahoo.comZynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023July 27, 2024 | Paradigm Press (Ad)Musk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840.September 27, 2023 | bizjournals.comHarmony Biosciences extends deadline for Zynerba shareholders on up to $200M dealSeptember 14, 2023 | finance.yahoo.comInsider Sell: President Terri Sebree Sells 12,401 Shares of Zynerba Pharmaceuticals IncSeptember 14, 2023 | finance.yahoo.comZynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research SymposiumAugust 16, 2023 | msn.comHC Wainwright & Co. Downgrades Zynerba Pharmaceuticals (ZYNE)August 15, 2023 | finance.yahoo.comIs Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Deliver On Growth Plans?August 14, 2023 | marketwatch.comZynerba Pharmaceuticals Shares Soar on Harmony Biosciences Deal >ZYNEAugust 14, 2023 | markets.businessinsider.comCrude Oil Down 1%; Zynerba Pharmaceuticals Shares Spike HigherAugust 14, 2023 | technews.tmcnet.comZYNE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Zynerba Pharmaceuticals, Inc. Is Fair to ShareholdersAugust 14, 2023 | finance.yahoo.comHARMONY BIOSCIENCES TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC.See More Headlines Receive ZYNE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zynerba Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2023Today7/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ZYNE CUSIPN/A CIK1621443 Webwww.zynerba.com Phone(484) 581-7505FaxN/AEmployees25Year FoundedN/APrice Target and Rating Average Stock Price Target$1.11 High Stock Price Target$1.11 Low Stock Price Target$1.11 Potential Upside/Downside-14.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,040,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-90.03% Return on Assets-72.62% Debt Debt-to-Equity RatioN/A Current Ratio3.43 Quick Ratio3.43 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.01 per share Price / Book1.29Miscellaneous Outstanding Shares53,939,000Free Float46,905,000Market Cap$70.12 million OptionableOptionable Beta1.32 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Armando Anido MBA (Age 65)Chairman & CEO Comp: $934.53kMs. Terri B. Sebree (Age 65)Pres Comp: $729.15kMr. James E. Fickenscher (Age 59)CFO & VP of Corp. Devel. (Leave of Absence) Comp: $607.62kMr. Kenneth T. Jones (Age 59)VP, Corp. Controller & Interim CFO Mr. Albert P. Parker II (Age 57)Chief Legal Officer & Corp. Sec. Mr. Joseph ApostolicoVP of HRMore ExecutivesKey CompetitorsOvid TherapeuticsNASDAQ:OVIDAytu BioPharmaNASDAQ:AYTUNektar TherapeuticsNASDAQ:NKTRMersana TherapeuticsNASDAQ:MRSNEliem TherapeuticsNASDAQ:ELYMView All CompetitorsInsidersArmando AnidoSold 17,830 sharesTotal: $23,713.90 ($1.33/share)Terri B SebreeSold 12,401 sharesTotal: $16,493.33 ($1.33/share)James E FickenscherSold 8,998 sharesTotal: $11,967.34 ($1.33/share)Brian RosenbergerSold 6,411 sharesTotal: $8,526.63 ($1.33/share)Kenneth T JonesSold 2,505 sharesTotal: $3,331.65 ($1.33/share) ZYNE Stock Analysis - Frequently Asked Questions How were Zynerba Pharmaceuticals' earnings last quarter? Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) released its quarterly earnings results on Monday, May, 15th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.19) by $0.02. When did Zynerba Pharmaceuticals IPO? Zynerba Pharmaceuticals (ZYNE) raised $42 million in an initial public offering (IPO) on Wednesday, August 5th 2015. The company issued 3,000,000 shares at $13.00-$15.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Canaccord Genuity and Oppenheimer & Co. were co-managers. What other stocks do shareholders of Zynerba Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zynerba Pharmaceuticals investors own include Cara Therapeutics (CARA), GW Pharmaceuticals (GWPH), Cronos Group (CRON), NVIDIA (NVDA) and Advanced Micro Devices (AMD). This page (NASDAQ:ZYNE) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal war...Behind the Markets | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zynerba Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zynerba Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.